Compare

InMed Pharmaceuticals Inc. vs Lexaria Bioscience Corp. vs International Stem Cell Corp vs Azitra, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearInMed Pharmaceuticals Inc.
MTRI
Lexaria Bioscience Corp.
LEXX
International Stem Cell Corp
ISCO
Azitra, Inc.
AZTR
Year ended2026-06-302025-08-312025-12-312025-12-31
Revenuen/a$705.9K$9.10M$0
Revenue growth (YoY)n/a+52.0%+0.2%-100.0%
Gross marginn/a99.6%55.7% (computed)n/a
Operating marginn/an/m-2.9%n/a
Net marginn/an/m-4.6%n/a
Net income-$12.56M-$11.90M-$418.0K-$10.96M
EPS (Diluted)-$3.12-$0.66-$0.05-$2.25
Operating cash flow-$8.64M-$10.45M$8.0K-$11.22M
Free cash flown/a-$10.48M-$35.0K-$11.25M
Cash & equivalentsn/an/an/a$2.07M
Total assets$3.03M$4.18M$4.82M$5.03M
Total liabilities$1.96M$1.57M$4.58M$1.22M
Shareholders' equity$1.08M$2.99M-$4.06M$3.80M
Return on year-end equityn/m-398.1%n/a-288.2%
Shares outstanding5.34M19.56M8.00M10.74M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearInMed Pharmaceuticals Inc.Lexaria Bioscience Corp.International Stem Cell CorpAzitra, Inc.
Latest$4.94M
Ended 2025-06-30
$705.9K
Ended 2025-08-31
$9.10M
Ended 2025-12-31
$0
Ended 2025-12-31
1 year earlier$4.60M
Ended 2024-06-30
$464.3K
Ended 2024-08-31
$9.09M
Ended 2024-12-31
$7.5K
Ended 2024-12-31
2 years earlier$4.14M
Ended 2023-06-30
$226.2K
Ended 2023-08-31
$7.79M
Ended 2023-12-31
$686.0K
Ended 2023-12-31
3 years earlier$1.09M
Ended 2022-06-30
$255.4K
Ended 2022-08-31
$8.18M
Ended 2022-12-31
$284.0K
Ended 2022-12-31
4 years earliern/a$722.7K
Ended 2021-08-31
$7.18M
Ended 2021-12-31
n/a